Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma

• Verfasst von: Frühauf, Stefan [VerfasserIn]
• Verfasst von: Klaus, Johanna [VerfasserIn]
• Verfasst von: Hüsing, Johannes [VerfasserIn]
• Verfasst von: Veldwijk, Marlon Romano [VerfasserIn]
• Verfasst von: Buß, Eike Christian [VerfasserIn]
• Verfasst von: Topaly, Julian [VerfasserIn]
• Verfasst von: Seeger, Timon [VerfasserIn]
• Verfasst von: Zeller, L. [VerfasserIn]
• Verfasst von: Möhler, Thomas [VerfasserIn]
• Verfasst von: Ho, Anthony Dick [VerfasserIn]
• Verfasst von: Goldschmidt, Hartmut [VerfasserIn]
• Titel: Efficient mobilization of peripheral blood stem cells following CAD chemotherapy and a single dose of pegylated G-CSF in patients with multiple myeloma
• Verf.angabe: S. Fruehauf, J. Klaus, J. Huesing, M.R. Veldwijk, E.C. Buss, J. Topaly, T. Seeger, L.W.J. Zeller, T. Moehler, A.D. Ho and H. Goldschmidt
• E-Jahr: 2007
• Jahr: 23 April 2007
• Umfang: 8 S.
• Fussnoten: Gesehen am 01.03.2021
• Titel Quelle: Enthalten in: Bone marrow transplantation
• Ort Quelle: London : Springer Nature, 1997
• Jahr Quelle: 2007
• Band/Heft Quelle: 39(2007), 12, Seite 743-750
• ISSN Quelle: 1476-5365
• DOI: doi:10.1038/sj.bmt.1705675
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Adult
• Sach-SW: Aged
• Sach-SW: Antigens, CD34
• Sach-SW: Antineoplastic Combined Chemotherapy Protocols
• Sach-SW: Blood Component Removal
• Sach-SW: Cell Count
• Sach-SW: Combined Modality Therapy
• Sach-SW: Cyclophosphamide
• Sach-SW: Dexamethasone
• Sach-SW: Doxorubicin
• Sach-SW: Female
• Sach-SW: Filgrastim
• Sach-SW: Granulocyte Colony-Stimulating Factor
• Sach-SW: Hematopoietic Stem Cell Mobilization
• Sach-SW: Hematopoietic Stem Cells
• Sach-SW: Humans
• Sach-SW: Male
• Sach-SW: Middle Aged
• Sach-SW: Multiple Myeloma
• Sach-SW: Polyethylene Glycols
• Sach-SW: Recombinant Proteins
• K10plus-PPN: 1750037718

Abstract

High-dose chemotherapy followed by autologous blood stem cell transplantation is the standard treatment for myeloma patients. In this study, CAD (cyclophosphamide, adriamycin, dexamethasone) chemotherapy and a single dose of pegfilgrastim (12 mg) was highly effective in mobilizing peripheral blood stem cells (PBSCs) for subsequent transplantation, with 88% of patients (n = 26) achieving the CD34+ cell harvest target of > or = 7.50 x 10(6) CD34+ cells/kg body weight, following a median of two apheresis procedures (range 1-4) and with first apheresis performed at a median day 13 after CAD application (range 10-20). Patients treated with pegfilgrastim showed a reduced time to first apheresis procedure from mobilization compared with filgrastim-mobilized historical matched controls (n = 52, P = 0.015). The pegfilgrastim mobilization regimen allowed for transplantation of a median of 3.58 x 10(6) CD34+ cells/kg body weight while leaving sufficient stored cells for a second high-dose regimen and back-ups in most patients. Engraftment following transplantation was comparable to filgrastim, with a median time of 14 days to leucocyte > or =1.0 x 10(9)/l (range 10-21) and 11 days to platelets > or = 20 x 10(9)/l (range 0-15). The results of this study thus provide further support for the clinical utility of pegfilgrastim for the mobilization of PBSC following chemotherapy in cancer patients scheduled for transplantation.